Owners, management and financials
CVR: 40010106
DKK -27,482
Gross profit
Net result: DKK -25,574
LJP HOLDING ApS (100%)
CVR · view owners
John Pedersen
Board: 2 members
CVR · view management
Active
Founded 19 September 2018
CVR · view overview
0 employees
Annual report 2025 · average
Director registered: John Pedersen
CVR · 19/09/2018
View the full event history
Neuprozyme Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2018. The company is registered under the industry Fremstilling af andre organiske basiskemikalier. The management consists of John Pedersen. The board consists of John Pedersen and Lone Ballegaard Pedersen. The company is owned by LJP HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -27,482 and a net result of DKK -25,574 compared with DKK -24,871 the year before. Equity in the 2025 report amounted to DKK 82,360.
Selskabets formål er at udvikle og sælge farmaceutiske produkter.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/07/2024 – 30/06/2025 | -27 t. | -26 t. | 109 t. | 82 t. | 0 | |
| 202401/07/2023 – 30/06/2024 | -27 t. | -25 t. | 133 t. | 108 t. | - | |
| 202301/07/2022 – 30/06/2023 | -1 t. | -21 t. | 158 t. | 133 t. | - | |
| 202201/07/2021 – 30/06/2022 | 576 t. | 436 t. | 1.7 mio. | 154 t. | - | |
| 202101/07/2020 – 30/06/2021 | 1 mio. | -289 t. | 49 t. | -282 t. | - | |
| 202001/07/2019 – 30/06/2020 | -39 t. | -36 t. | 63 t. | 7 t. | 0 | |
| 201901/07/2018 – 30/06/2019 | -8 t. | -8 t. | 52 t. | 43 t. | - | |
| 201801/07/2017 – 30/06/2018 | - | 0 | 50 t. | 50 t. | - |
Compared to 14 companies in Fremstilling af andre organiske basiskemikalier
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of Neuprozyme Therapeutics ApS is 40010106.
Neuprozyme Therapeutics ApS is owned by LJP HOLDING ApS.
The management of Neuprozyme Therapeutics ApS consists of John Pedersen.
The board of Neuprozyme Therapeutics ApS consists of John Pedersen and Lone Ballegaard Pedersen.
In 2025, Neuprozyme Therapeutics ApS reported a gross profit of DKK -27,482.
Neuprozyme Therapeutics ApS had an average of 0 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Neuprozyme Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK -27,482, and the net result was DKK -25,574.
Neuprozyme Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -26,502, and the net result was DKK -24,871.
Neuprozyme Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -1,074, and the net result was DKK -21,211.
Neuprozyme Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK 576,182, and the net result was DKK 436,098.
Neuprozyme Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK 1,031,282, and the net result was DKK -289,040.
Neuprozyme Therapeutics ApS has published its annual report for 2020. Gross profit came to DKK -38,600, and the net result was DKK -35,542.
As of October 28, 2020, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has been appointed auditor of Neuprozyme Therapeutics ApS.
As of October 28, 2020, ALBJERG STATSAUTORISERET REVISIONSAKTIESELSKAB has stepped down as auditor of Neuprozyme Therapeutics ApS.
Neuprozyme Therapeutics ApS has published its annual report for 2019. Gross profit came to DKK -7,500, and the net result was DKK -7,500.
Neuprozyme Therapeutics ApS has published its annual report for 2018. The net result was DKK 0.
As of September 19, 2018, ALBJERG STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of Neuprozyme Therapeutics ApS.
As of September 19, 2018, Lone Ballegaard Pedersen has joined the board of directors of Neuprozyme Therapeutics ApS.
As of September 19, 2018, John Pedersen has joined the board of directors of Neuprozyme Therapeutics ApS.
As of September 19, 2018, John Pedersen is registered as director of Neuprozyme Therapeutics ApS.
As of September 19, 2018, LJP HOLDING ApS is registered as an owner of Neuprozyme Therapeutics ApS with an ownership share of 100%.
Neuprozyme Therapeutics ApS was founded on September 19, 2018.
Companies in the same industry and area
CVR 13917094
CVR 40010114
CVR 46673123
CVR 40939008
